Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Multi-Modal AI-Driven Cohort Selection Tool to Predict Suboptimal Non-Responders to Aflibercept Loading-Phase for Neovascular Age-Related Macular Degeneration: PRECISE Study Report 1.
Chorev M, Haderlein J, Chandra S, Menon G, Burton BJL, Pearce I, McKibbin M, Thottarath S, Karatsai E, Chandak S, Kotagiri A, Talks J, Grabowska A, Ghanchi F, Gale R, Hamilton R, Antony B, Garnavi R, Mareels I, Giani A, Chong V, Sivaprasad S. Chorev M, et al. Among authors: mckibbin m. J Clin Med. 2023 Apr 20;12(8):3013. doi: 10.3390/jcm12083013. J Clin Med. 2023. PMID: 37109349 Free PMC article.
UNITED KINGDOM DATABASE STUDY OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX) FOR MACULAR EDEMA RELATED TO RETINAL VEIN OCCLUSION.
Soliman MK, Zarranz-Ventura J, Chakravarthy U, McKibbin M, Brand C, Menon G, Cilliers H, Natha S, Ross A, Sarhan M, Lobo A, Chong V, Mahmood S, Islam N, Akerele T, Shakarchi A, Sallam A; United Kingdom Ozurdex in Retinal Vein Occlusion Electronic Medical Records (UK Ozurdex RVO EMR) Users Group. Soliman MK, et al. Among authors: mckibbin m. Retina. 2023 Apr 1;43(4):679-687. doi: 10.1097/IAE.0000000000003698. Retina. 2023. PMID: 36729561
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, Grossi F, Baumal CR, Korobelnik JF, Slakter JS, Waheed NK, Metlapally R, Pearce I, Steinle N, Francone AA, Hu A, Lally DR, Deschatelets P, Francois C, Bliss C, Staurenghi G, Monés J, Singh RP, Ribeiro R, Wykoff CC; OAKS and DERBY study investigators. Heier JS, et al. Lancet. 2023 Oct 21;402(10411):1434-1448. doi: 10.1016/S0140-6736(23)01520-9. Lancet. 2023. PMID: 37865470 Clinical Trial.
UK Neovascular Age-Related Macular Degeneration Database. Report 6: time to retreatment after a pause in therapy. Outcomes from 92 976 intravitreal ranibizumab injections.
Madhusudhana KC, Lee AY, Keane PA, Chakravarthy U, Johnston RL, Egan CA, Sim D, Zarranz-Ventura J, Tufail A, McKibbin M; UK AMD EMR Study Group. Madhusudhana KC, et al. Among authors: mckibbin m. Br J Ophthalmol. 2016 Dec;100(12):1617-1622. doi: 10.1136/bjophthalmol-2015-308077. Epub 2016 Mar 30. Br J Ophthalmol. 2016. PMID: 27030276
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Shimura M, et al. Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10. Jpn J Ophthalmol. 2023. PMID: 36897413 Free PMC article. Clinical Trial.
A foundation model for generalizable disease detection from retinal images.
Zhou Y, Chia MA, Wagner SK, Ayhan MS, Williamson DJ, Struyven RR, Liu T, Xu M, Lozano MG, Woodward-Court P, Kihara Y; UK Biobank Eye & Vision Consortium; Altmann A, Lee AY, Topol EJ, Denniston AK, Alexander DC, Keane PA. Zhou Y, et al. Nature. 2023 Oct;622(7981):156-163. doi: 10.1038/s41586-023-06555-x. Epub 2023 Sep 13. Nature. 2023. PMID: 37704728 Free PMC article.
Deep Ocular Phenotyping Across Primary Open-Angle Glaucoma Genetic Burden.
Sekimitsu S, Xiang D, Smith SL, Curran K, Elze T, Friedman DS, Foster PJ, Luo Y, Pasquale LR, Peto T, Segrè AV, Shweikh Y, Warwick A, Zhao Y, Wiggs JL, Zebardast N; UK Biobank Eye and Vision Consortium. Sekimitsu S, et al. JAMA Ophthalmol. 2023 Sep 1;141(9):891-899. doi: 10.1001/jamaophthalmol.2023.3645. JAMA Ophthalmol. 2023. PMID: 37589995
219 results